Related Experiment Video
Updated: Apr 7, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Mepolizumab exhibits quantifiable reduction in corticosteroid-related adverse effects in severe asthma
Njira L Lugogo1, Jared Silver2, William W Busse3
1Division of Pulmonary Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
Background:
Treatment that reduces systemic corticosteroid (SCS)-related adverse effects but maintains disease control is of broad public health importance.
Objective:
To evaluate the effect of mepolizumab vs long-term SCS use on SCS-related adverse effects in patients with severe asthma.
Methods:
This retrospective, longitudinal cohort study (GSK Identification: US 218950) used claims data from the Optum Clinformatics Data Mart database from November 2014 to December 2022. Eligible patients (aged ≥12 years with ≥2 asthma diagnostic claims), had at least 2 mepolizumab claims (mepolizumab-treated cohort) or at least 6 months of continuous SCS use (long-term SCS-treated cohort). Inverse probability of treatment weighting was used to balance cohort characteristics. The primary outcome was SCS-related adverse effects. The secondary outcomes included exacerbation frequency, SCS/oral corticosteroid use, healthcare resource utilization, and costs (excluding the cost of therapy).
Results:
Overall, 1219 (mepolizumab-treated) and 835 (long-term SCS-treated) patients with severe asthma were included (median follow-up, 12 months). Cohorts were well-balanced after weighting (mean age, 63-65 years; 66% female). The mepolizumab-treated cohort had significant reductions in overall, acute, and long-term SCS-related adverse effects (rate ratio [CI] 0.80 [0.70-0.92], 0.63 [0.47-0.84], and 0.80 [0.70-0.92], respectively) vs the long-term SCS-treated cohort; SCS dose reduction of 4.7 mg/d corresponds to a 20% reduction in SCS-related adverse effects (P = .002). Similar trends were observed in exacerbation rates, healthcare resource utilization, and medical costs, although not all reached statistical significance.
Conclusion:
Mepolizumab treatment reduced acute and long-term corticosteroid effects in patients with severe asthma vs long-term SCS use, suggesting avoidance of corticosteroid use can lead to measurable regression of SCS-associated adverse effects and more favorable disease trajectory.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...